The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis: Results of Phase 1/2 and 2a Clinical Trials
Open accessAbstract
IMPORTANCE: Preclinical studies have shown that neurotrophic growth factors (NTFs) extend the survival of motor neurons in amyotrophic lateral sclerosis (ALS) and that the combined delivery of these neurotrophic factors has a strong synergistic effect. We have developed a culture-based method for inducing mesenchymal stem cells (MSCs) to secrete neurotrophic factors. These MSC-NTF cells have been shown to be protective in several animal models of neurodegenerative diseases. OBJECTIVE: To determine the safety and possible clinical efficacy of autologous MSC-NTF cells transplantation in patients with ALS. DESIGN, SETTING, AND PARTICIPANTS: In these open-label proof-of-concept studies, patients with ALS were enrolled between June 2011 and October 2014 at the Hadassah Medical Center in Jerusalem, Israel. All patients were followed up for 3 months before transplantation and 6 months after transplantation. In the phase 1/2 part of the trial, 6 patients with early-stage ALS were injected intramuscularly (IM) and 6 patients with more advanced disease were transplanted intrathecally (IT). In the second stage, a phase 2a dose-escalating study, 14 patients with early-stage ALS received a combined IM and IT transplantation of autologous MSC-NTF cells. INTERVENTIONS: Patients were administered a single dose of MSC-NTF cells. MAIN OUTCOMES AND MEASURES: The primary end points of the studies were safety and tolerability of this cell therapy. Secondary end points included the effects of the treatment on various clinical parameters, such as the ALS Functional Rating Scale-Revised score and the respiratory function. RESULTS: Among the 12 patients in the phase 1/2 trial and the 14 patients in the phase 2a trial aged 20 and 75 years, the treatment was found to be safe and well tolerated over the study follow-up period. Most of the adverse effects were mild and transient, not including any treatment-related serious adverse event. The rate of progression of the forced vital capacity and of the ALS Functional Rating Scale-Revised score in the IT (or IT+IM)-treated patients was reduced (from -5.1% to -1.2%/month percentage predicted forced vital capacity, P < .04 and from -1.2 to 0.6 ALS Functional Rating Scale-Revised points/month, P = .052) during the 6 months following MSC-NTF cell transplantation vs the pretreatment period. Of these patients, 13 (87%) were defined as responders to either ALS Functional Rating Scale-Revised or forced vital capacity, having at least 25% improvement at 6 months after treatment in the slope of progression. CONCLUSIONS AND RELEVANCE: The results suggest that IT and IM administration of MSC-NTF cells in patients with ALS is safe and provide indications of possible clinical benefits, to be confirmed in upcoming clinical trials. TRIAL REGISTRATION: clinicaltrials.gov Identifiers: NCT01051882 and NCT01777646.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis
Brooks, B. R., Miller, R. G., Swash, M., & Munsat, T. L. (2000) · Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders · doi:10.1080/146608200300079536 · Cited by 5,433
Karussis, D., Karageorgiou, C., Vaknin-Dembinsky, A., Gowda-Kurkalli, B., Gomori, J. M., Kassis, I., Bulte, J. W. M., Petrou, P., Ben-Hur, T., Abramsky, O., et al. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.248 · Cited by 941
Self-citationConnick, P., Kolappan, M., Crawley, C., Webber, D. J., Patani, R., Michell, A. W., Du, M.-Q., Luan, S.-L., Altmann, D. R., Thompson, A. J., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70305-2 · Cited by 607
Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS
Kimura, F., Fujimura, C., Ishida, S., Nakajima, H., Furutama, D., Uehara, H., Shinoda, K., Sugino, M., & Hanafusa, T. (2006) · Neurology · doi:10.1212/01.wnl.0000194316.91908.8a · Cited by 564
A controlled trial of recombinant methionyl human BDNF in ALS
The BDNF Study Group (Phase III) (1999) · Neurology · doi:10.1212/wnl.52.7.1427 · Cited by 451
Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS
Gordon, P. H., & Cheung, Y. K. (2006) · Neurology · doi:10.1212/01.wnl.0000243812.25517.87 · Cited by 435
The “Dying-Back” Phenomenon of Motor Neurons in ALS
Dadon-Nachum, M., Melamed, E., & Offen, D. (2011) · Journal of Molecular Neuroscience · doi:10.1007/s12031-010-9467-1 · Cited by 412
Self-citationMesenchymal stem cell transplantation in amyotrophic lateral sclerosis: A Phase I clinical trial
Mazzini, L., Ferrero, I., Luparello, V., Rustichelli, D., Gunetti, M., Mareschi, K., Testa, L., Stecco, A., Tarletti, R., Miglioretti, M., et al. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.08.007 · Cited by 396
Miller, R. G., Petajan, J. H., Bryan, W. W., Armon, C., Barohn, R. J., Goodpasture, J. C., Hoagland, R. J., Parry, G. J., Ross, M. A., Stromatt, S. C., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410390215 · Cited by 345
Kassis, I., Grigoriadis, N., Gowda-Kurkalli, B., Mizrachi-Kol, R., Ben-Hur, T., Slavin, S., Abramsky, O., & Karussis, D. (2008) · Archives of Neurology · doi:10.1001/archneur.65.6.753 · Cited by 339
Self-citationImmune-mediated Mechanisms in the Pathoprogression of Amyotrophic Lateral Sclerosis
Zhao, W., Beers, D. R., & Appel, S. H. (2013) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-013-9489-x · Cited by 300
Johann, S., Heitzer, M., Kanagaratnam, M., Goswami, A., Rizo, T., Weis, J., Troost, D., & Beyer, C. (2015) · Glia · doi:10.1002/glia.22891 · Cited by 277
Protective and Toxic Neuroinflammation in Amyotrophic Lateral Sclerosis
Hooten, K. G., Beers, D. R., Zhao, W., & Appel, S. H. (2015) · Neurotherapeutics · doi:10.1007/s13311-014-0329-3 · Cited by 275
Glial cells in amyotrophic lateral sclerosis
Philips, T., & Rothstein, J. D. (2014) · Experimental Neurology · doi:10.1016/j.expneurol.2014.05.015 · Cited by 250
A randomized trial of mesenchymal stem cells in multiple system atrophy
Lee, P. H., Lee, J. E., Kim, H., Song, S. K., Lee, H. S., Nam, H. S., Cheong, J., Jeong, Y., Park, H., Kim, D. J., et al. (2012) · Annals of Neurology · doi:10.1002/ana.23612 · Cited by 234
Feldman, E. L., Boulis, N. M., Hur, J., Johe, K., Rutkove, S. B., Federici, T., Polak, M., Bordeau, J., Sakowski, S. A., & Glass, J. D. (2014) · Annals of Neurology · doi:10.1002/ana.24113 · Cited by 227
Mesenchymal stromal cell transplantation in amyotrophic lateral sclerosis: a long-term safety study
Mazzini, L., Mareschi, K., Ferrero, I., Miglioretti, M., Stecco, A., Servo, S., Carriero, A., Monaco, F., & Fagioli, F. (2012) · Cytotherapy · doi:10.3109/14653249.2011.613929 · Cited by 205
Llufriu, S., Sepúlveda, M., Blanco, Y., Marín, P., Moreno, B., Berenguer, J., Gabilondo, I., Martínez-Heras, E., Sola-Valls, N., Arnaiz, J.-A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113936 · Cited by 165
Uccelli, A., Milanese, M., Principato, M. C., Morando, S., Bonifacino, T., Vergani, L., Giunti, D., Voci, A., Carminati, E., Giribaldi, F., et al. (2012) · Molecular Medicine · doi:10.2119/molmed.2011.00498 · Cited by 160
Protective Effects of Neurotrophic Factor–Secreting Cells in a 6-OHDA Rat Model of Parkinson Disease
Sadan, O., Bahat-Stromza, M., Barhum, Y., Levy, Y. S., Pisnevsky, A., Peretz, H., Ilan, A. B., Bulvik, S., Shemesh, N., Krepel, D., et al. (2009) · Stem Cells and Development · doi:10.1089/scd.2008.0411 · Cited by 160
Self-citationMarconi, S., Bonaconsa, M., Scambi, I., Squintani, G. M., Rui, W., Turano, E., Ungaro, D., D’Agostino, S., Barbieri, F., Angiari, S., et al. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.05.034 · Cited by 157
The past, present and future of stem cell clinical trials for ALS
Thomsen, G. M., Gowing, G., Svendsen, S. P., & Svendsen, C. N. (2014) · Experimental Neurology · doi:10.1016/j.expneurol.2014.02.021 · Cited by 151
Synergistic Effects of GDNF and VEGF on Lifespan and Disease Progression in a Familial ALS Rat Model
Krakora, D., Mulcrone, P. L., Meyer, M., Lewis, C. M., Bernau, K., Gowing, G., Zimprich, C., Aebischer, P., Svendsen, C. N., & Suzuki, M. (2013) · Molecular Therapy · doi:10.1038/mt.2013.108 · Cited by 139
Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: where do we stand ?
Henriques (2010) · Frontiers in Neuroscience · doi:10.3389/fnins.2010.00032 · Cited by 134
Li, W., Brakefield, D., Pan, Y., Hunter, D., Myckatyn, T. M., & Parsadanian, A. S. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.08.028 · Cited by 126
Bone-marrow-derived mesenchymal stem cell therapy for neurodegenerative diseases
Sadan, O., Melamed, E., & Offen, D. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903321439 · Cited by 124
Self-citationClinical significance in the change of decline in ALSFRS-R
Castrillo‐Viguera, C., Grasso, D. L., Simpson, E., Shefner, J. M., & Cudkowicz, M. (2010) · Amyotrophic Lateral Sclerosis · doi:10.3109/17482960903093710 · Cited by 121
Boido, M., Piras, A., Valsecchi, V., Spigolon, G., Mareschi, K., Ferrero, I., Vizzini, A., Temi, S., Mazzini, L., Fagioli, F., et al. (2014) · Cytotherapy · doi:10.1016/j.jcyt.2014.02.003 · Cited by 98
Sadan, O., Shemesh, N., Barzilay, R., Dadon-Nachum, M., Blumenfeld‐Katzir, T., Assaf, Y., Yeshurun, M., Djaldetti, R., Cohen, Y., Melamed, E., et al. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2011.12.045 · Cited by 79
Self-citationDifferentiated Mesenchymal Stem Cells for Sciatic Nerve Injury
Dadon-Nachum, M., Sadan, O., Srugo, I., Melamed, E., & Offen, D. (2011) · Stem Cell Reviews and Reports · doi:10.1007/s12015-010-9227-1 · Cited by 66
Self-citationMesenchymal stromal cells prolong the lifespan in a rat model of amyotrophic lateral sclerosis
Forostyak, S., Jendelová, P., Kapcalová, M., Toro, D. A., & Syková, E. (2011) · Cytotherapy · doi:10.3109/14653249.2011.592521 · Cited by 66
Yan, K., Zhang, R., Sun, C., Chen, L., Li, P., Liu, Y., Peng, L., Sun, H., Qin, K., Chen, F., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0084116 · Cited by 65
Clinical experience with stem cells and other cell therapies in neurological diseases
Karussis, D. M., Petrou, P., & Kassis, I. (2012) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2012.09.031 · Cited by 52
Self-citationHegyi, B., Környei, Z., Ferenczi, S., Fekete, R., Kudlik, G., Kovács, K., Madarász, E., & Uher, F. (2014) · Stem Cells and Development · doi:10.1089/scd.2014.0088 · Cited by 51
Sadan, O., Shemesh, N., Cohen, Y., Melamed, E., & Offen, D. (2009) · PubMed · Cited by 43
Self-citationConnick, P., & Chandran, S. (2013) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-306573.25 · Cited by 41
Dadon-Nachum, M., Ben‐Yaakov, K., Ben‐Zur, T., Barhum, Y., Yaffe, D., Perlson, E., & Offen, D. (2014) · Journal of Molecular Neuroscience · doi:10.1007/s12031-014-0426-0 · Cited by 29
Self-citationSadan, O., Melamed, E., & Offen, D. (2012) · PLoS Currents · doi:10.1371/4f7f6dc013d4e · Cited by 27
Self-citationRare combination of myasthenia and motor neuronopathy, responsive to Msc‐Ntf stem cell therapy
Petrou, P., Argov, A., Lennon, V. A., Gotkine, M., Kassis, I., Vaknin‐Dembinsky, A., Ben‐Hur, T., Offen, D., Abramsky, O., Melamed, E., et al. (2013) · Muscle & Nerve · doi:10.1002/mus.24143 · Cited by 19
Self-citationClinical significance in the change of decline in ALSFRS-R
Castrillo‐Viguera, C., Grasso, D., Simpson, E., Shefner, J. M., & Cudkowicz, M. (2009) · Amyotrophic Lateral Sclerosis · doi:10.1080/17482960903093710 · Cited by 5
Cited by
Challenges and advances in clinical applications of mesenchymal stromal cells
Zhou, T., Yuan, Z., Weng, J., Pei, D., Du, X., He, C., & Lai, P. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01037-x · Cited by 712
Biological functions of mesenchymal stem cells and clinical implications
Naji, A., Eitoku, M., Favier, B., Deschaseaux, F., Rouas-Freiss, N., & Suganuma, N. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03125-1 · Cited by 624
Challenges and Controversies in Human Mesenchymal Stem Cell Therapy
Lukomska, B., Stanaszek, L., Zuba-Surma, E., Legosz, P., Sarzynska, S., & Drela, K. (2019) · Stem Cells International · doi:10.1155/2019/9628536 · Cited by 550
Mead, R. J., Shan, N., Reiser, H. J., Marshall, F., & Shaw, P. J. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00612-2 · Cited by 505
Leyane, T. S., Jere, S. W., & Houreld, N. N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137273 · Cited by 469
Metadata
- Authors
- Petrou, P., Gothelf, Y., Argov, Z., Gotkine, M., Levy, Y. S., Kassis, I., Vaknin-Dembinsky, A., Ben-Hur, T., Offen, D., Abramsky, O., Melamed, E., & Karussis, D.
- Venue
- JAMA Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2016-03-01
- Volume
- 73
- Issue
- 3
- Pages
- 337
- ISSN
- 2168-6149 (ISSN-L)
- OpenAlex
- W2234902113
- Cited by
- 303
- References
- 40
- FWCI
- 22.74
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.